Integra LifeSciences Holdings

Healthcare · Medical Devices

13.40$ +0.2% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Income Statement

Integra LifeSciences Holdings (IART) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 419 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement IART
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	250	256	259	282	279	369	357	366	366	383	360	384	379	395	354	259	370	389	360	390	387	406	377	398	385	398	381	381	382	397	369	418	381	443	383	416	402	435	392	419	1,648
Cost of Revenue	89	85	87	99	102	148	144	138	143	146	129	144	143	149	133	105	135	147	146	151	144	156	143	148	148	148	148	174	164	171	162	192	181	194	188	206	176	220	168	199	762
Gross Profit	161	170	172	183	177	220	213	229	223	237	231	240	236	246	221	153	235	242	214	239	242	249	234	249	237	250	233	207	218	226	207	226	200	249	194	209	226	215	224	220	885
Research & Development	15	14	15	16	15	17	18	19	20	20	18	18	19	26	21	15	19	22	22	20	26	25	24	26	25	27	27	27	27	24	27	30	27	31	25	27	22	25	24	24	95
Selling, General & Administrative	112	112	142	145	146	191	164	177	173	177	175	165	173	174	166	116	150	166	157	163	156	162	160	161	144	152	167	165	162	163	166	195	177	179	181	180	169	169	178	172	689
Total Operating Expenses	131	129	162	166	166	213	187	201	199	203	198	194	197	210	194	139	178	189	184	187	186	191	188	190	172	182	196	195	192	190	203	229	208	213	210	722	186	-341	184	200	230
Operating Income	30	41	10.0	17	11	7.2	26	28	24	34	32	46	-21	36	27	14	58	53	31	52	56	58	46	60	65	68	36	13	27	36	4.0	-3.0	-8.2	36	-15	-513	40	556	40	19	656
Interest Expense	6.3	6.5	5.1	6.2	6.8	17	19	18	14	14	13	13	14	13	18	16	21	17	13	13	12	12	12	12	13	13	12	12	13	14	14	19	19	19	20	21	23	24	27	23	96
Pre-Tax Income	25	35	4.7	8.0	3.2	-4.6	9.1	13	11	25	25	36	-28	26	11	1.7	42	39	67	45	51	52	39	52	59	64	30	3.8	19	29	-5.2	-15	-20	23	-30	-531	-6.8	4.3	-2.4	4.7	-0.2
Income Tax Expense	4.9	7.2	-1.6	-2.8	0.1	-49	-1.9	1.4	-2.3	-0.6	-7.9	6.6	0.1	11	2.3	2.0	9.2	-54	22	9.8	7.6	6.4	6.4	6.8	8.9	11	5.6	-0.4	-0.9	9.0	-1.9	-2.8	-9.7	3.1	-4.7	-47	-1.4	6.0	2.2	0.3	7.1
Net Income	20	28	6.4	11	3.2	44	11	11	13	25	33	30	-28	15	9.2	-0.4	32	93	45	35	43	45	33	45	50	53	24	4.2	19	20	-3.3	-12	-11	19	-25	-484	-5.4	-1.7	-4.6	4.5	-7.2
EBITDA	59	60	55	63	63	87	84	85	85	91	65	61	-8.3	68	58	47	93	82	105	83	88	90	75	95	103	104	74	47	62	74	39	40	35	79	26	-472	54	66	63	66	250

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings